New trials, publications, preprints and grants on this target, month by month.
Trial
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants Previously Treated, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
6 Jan 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
23 Nov 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors.
6 Nov 2026· The oncologist· PUBMED
Publication
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
3 Nov 2026· Molecular cancer therapeutics· PUBMED
Publication
EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study.
2 Nov 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Trial
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
1 Nov 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Profiling EGFR, c-MET, and B7H3 co-expression to guide next-generation dual-drug conjugate strategies in colorectal cancer.
1 Nov 2026· The journal of pathology. Clinical research· PUBMED
Publication
c-MET Inhibition Is Accompanied by PD-L1 Upregulation and Immunosuppression-Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti-PD-1 Therapy.
1 Nov 2026· Cancer medicine· PUBMED
Publication
B Cell Deficiency Protects Against the Development of c-MET and Beta-Catenin Driven Hepatocellular Carcinoma in Mice.
1 Nov 2026· Cell biology international· PUBMED
Trial
ASKC202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
30 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publication
Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.
26 Oct 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Cost-Effectiveness of Telisotuzumab Vedotin-tllv for Previously Treated High c-Met Protein-Overexpressing Nonsquamous Non-Small Cell Lung Cancer in the United States.
15 Oct 2026· Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research· PUBMED
Publication
HIV-1 hijacks HGF/c-MET signaling to promote viral entry and replication in primary CD4+ T cells.
14 Oct 2026· mBio· PUBMED
Publication
Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
12 Oct 2026· Current oncology (Toronto, Ont.)· PUBMED
Publication
Immunohistochemistry for c-MET, HLA class II, and CD68 does not show prognostic value in early-stage classic Hodgkin lymphoma patients in the EORTC-GELA H9 intergroup randomised trial.
8 Oct 2026· PloS one· PUBMED
Publication
Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report.
7 Oct 2026· The oncologist· PUBMED
Publication
Comparative Immunohistochemical Analysis of FAP and c-MET Expression Across Renal Cell Carcinoma Subtypes: Preliminary Results and Potential Theranostic Implications.
6 Oct 2026· Diagnostics (Basel, Switzerland)· PUBMED
Publication
Reclassification of Noncanonical MET Splice-Site Variants Using RNA-Based Validation: A Practical Diagnostic Approach in Non-Small Cell Lung Cancer.
2 Oct 2026· Turk patoloji dergisi· PUBMED
Trial
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
1 Oct 2026· PHASE1_PHASE2 · RECRUITING· CTGOV
Trial
Gematinib Combined With Lenvatinib for the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With MET Protein Overexpression: A Prospective, Multicenter, Phase II Clinical Study
30 Sept 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
c-MET/NF-κB axis modulates PD-L1 and CCL22-mediated immune evasion and its inhibition enhances anti-PD-1 efficacy in non-small cell lung cancer.
30 Sept 2026· International immunopharmacology· PUBMED
Publication
Erratum: Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma.
24 Sept 2026· Hepatology (Baltimore, Md.)· PUBMED
Publication
Prognostic significance of co-expression of c-MET and EGFR in locally advanced and metastatic gastric cancer: a retrospective cohort study.
24 Sept 2026· Frontiers in oncology· PUBMED
Publication
Longitudinal Assessment of EGFR and MET Transcriptional Activity Using Cell-Free Chromatin Immunoprecipitation in Two Patients with EGFR-Mutated Non-Small Cell Lung Cancer.
23 Sept 2026· Cancers· PUBMED
Publication
Novel 1-benzyl-oxindole indole hybrids targeting PDGFR-β, SRC, and c-MET signaling and inducing caspase-3-dependent apoptosis in pancreatic cancer cells.
17 Sept 2026· European journal of medicinal chemistry· PUBMED
Publication
Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.
17 Sept 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
A Dual-Ligand PDC Co-Targeting FOLR1 and c-Met Enhances Tumor Accumulation and Antitumor Efficacy in Ovarian Cancer.
17 Sept 2026· Cancers· PUBMED
Publication
Exploring spatial heterogeneity of PD-L1 and c-MET expression in oral squamous cell carcinoma.
16 Sept 2026· Oral and maxillofacial surgery· PUBMED
Publication
Thieno[2,3-d]pyrimidine scaffold optimization for synergistic c-Met/STAT3 blockade: Synthesis, structure-activity relationships, in vitro potency, and apoptotic pathways in colorectal cancer.
15 Sept 2026· Bioorganic chemistry· PUBMED
Publication
HGF/c-MET signaling induces glutamine metabolism in MET-amplified head and neck squamous cell carcinoma via MAPK/ERK-dependent induction of GLS-1.
15 Sept 2026· Medical oncology (Northwood, London, England)· PUBMED